Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) AI Stock Analysis

4 Followers

Guangzhou Baiyunshan Pharmaceutical Holdings Company

(Other OTC:GZPHF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthStrong 28% TTM revenue growth indicates that the company is expanding its sales base across pharmaceutical and healthcare activities. If sustained, this growth can improve operating scale, support reinvestment in products and distribution, and reinforce its position across hospital and consumer channels.

Negative Factors

Margin CompressionThe decline in net margin shows that revenue growth is not translating proportionally into earnings. Continued compression in net, EBITDA and operating margins could limit internal funding, reduce the benefit of scale, and make future profitability more dependent on product mix and cost control.

Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $6.20B
Dividend Yield: 4.71%
Average Volume (3M): ―
Price to Earnings (P/E): 14.7
Beta (1Y): -0.01
Revenue Growth: 5.68%
EPS Growth: -23.34%
Country: US
Employees: 27,057
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model

Company Description

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditiona...

Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GZPHF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:3320	79Outperform	HKD 29.06B	6.11	7.92%	5.28%	7.94%	52.83%
HK:1513	74Outperform	HKD 29.06B	17.83	11.32%	6.32%	-9.56%	-23.22%
HK:0867	61Neutral	HKD 25.71B	14.26	8.60%	3.31%	14.80%	-2.88%
HK:2196	57Neutral	HKD 67.71B	17.23	7.14%	2.69%	9.88%	9.30%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
HK:0512	55Neutral	HKD 15.72B	13.63	6.61%	3.87%	7.35%	-45.49%

* General Sector Average

Performance Comparison

GZPHF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GZPHF	Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H	2.34	0.11	4.89%
HK:0867	China Medical System Holdings	10.39	-3.38	-24.57%
HK:1513	Livzon Pharmaceutical Group Class H	24.62	-4.45	-15.32%
HK:2196	Shanghai Fosun Pharmaceutical (Group) Co Class H	16.73	-5.74	-25.54%
HK:3320	China Resources Pharmaceutical Group Ltd.	4.54	-0.22	-4.64%
HK:0512	Grand Pharmaceutical Group Limited	4.37	-4.10	-48.38%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Guangzhou Baiyunshan Pharmaceutical Holdings Company AI Stock Analysis